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logical dimension. Correlation coefficients in patients
clinically stable between D0 and D28; were all greater
than 0.84 for all dimensions of ULL-27. The sensitivity
analysis between D0 and D28 in patients with active dis-
ease demonstrated significant differences between mean
scores for all ULL-27 dimensions.
CONCLUSION: Volume of oedema poorly reflects the
impact of the illness upon the patient. The ULL- 27 scale
seems to be a consistent instrument.
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OBJECTIVES: Selecting conservative therapies for men
with non-metastatic prostate cancer involves trade-offs
between treatment attributes. An interview-based survey
using conjoint analysis was undertaken to establish
which treatment attributes are important to men in se-
lecting treatments, and how attributes are traded off.
METHODS: On the basis a pilot study, eight treatment-
related attributes were selected for the survey: diarrhea;
hot flushes; ability to maintain an erection; breast swell-
ing/tenderness; physical energy; sex drive; life expect-
ancy, and out-of-pocket personal costs. A discrete choice
preference elicitation mechanism was used. One hundred
eighty men with non-metastatic prostate cancer from two
London hospitals were invited to participate. Of these,
129 men, mean age of 70 years, 58% T-stage 1 or 2 at di-
agnosis, were interviewed. Data were analyzed using ran-
dom effects probit models.
RESULTS: On average, men’s responses to the conjoint
questions were sensitive to variation in the levels of all at-
tributes (p  .01) and coefficient signs on all attributes
were as expected. A statistically significant interaction
was shown which indicated that the attribute ability ‘to
maintain an erection’ was less important to older men (p 
.001). Most men were willing to make trade-offs between
avoiding side effects and both losses in life expectancy
and out-of-pocket costs. In terms of the former, they
were, on average, most willing to forgo life expectancy to
avoid limitations in physical energy (mean of 3.01
months), and least willing to trade life expectancy to
avoid hot flushes (mean of 0.58 months to move from
‘moderate’ to ‘mild’ or ‘mild’ to ‘none’).
CONCLUSIONS: Men with prostate cancer are willing
and able to participate in a relatively complex exercise
that weighs-up the benefits and harms of various conser-
vative treatments for their condition, and to make trade-
offs between attributes. The results provide an indication
of the relative importance of different aspects of treat-
ment to patients with prostate cancer.
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OBJECTIVE: To compare patients’ own global health as-
sessment item of the SF-36 (SF-1) and investigators’ glo-
bal health assessment (GLBHLT) with values calculated
for Health Utilities Index (HUI-III) and SF-36 preference-
based (SF-6D), in patients with coronary artery disease
(CAD). SF-1 is considered a coarse measure for patients’
own health assessment while GLBHLT is a widely used
clinical-trials endpoint.
METHODS: Baseline data of the SF-36, HUI-III and
GLBHLT were collected for 331 patients enrolled in a
double-blind, multinational, phase III clinical trial. Both
the SF-1 and GLBHLT rate patients’ health on a scale of
one to five, where one is excellent and five is poor.
RESULTS: Correlation coefficients (r) between the SF-1
and HUI-III, and the SF-1 and SF-6D were 0.501, 0.508,
respectively (p  .001). An r  0.27 between the SF-1 and
GLBHLT was found significant, albeit the magnitude
was almost half of those calculated for the SF-1 and SF-6D
or the SF-1 and HUI-III. Calculated SF-6D and HUI-III
values for GLBHLT  1 (excellent) were 0.74 and 0.74
compared with the corresponding SF-1 values of 0.81
and 0.83, respectively. Also the SF-6D and HUI-III values
for GLBHLT  5 (poor) were 0.59 and 0.43 compared
with the corresponding SF-1 values of 0.54 and 0.21, re-
spectively.
CONCLUSION: The SF-1 as a rough estimate of the pa-
tient’s own health, yielded a stronger correlation with
utilities calculated for HUI-III and SF-6D while GL-
BHLT, considered a routine measure in clinical trials,
yielded much weaker correlation. Confirmation of these
findings is needed to assess if GLBHLT is a fair represen-
tation of the health of patients with CAD.
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OBJECTIVES: Obesity is a very common condition in
type 2 diabetic patients. Treating obesity may enhance
hypoglycemic treatment and, thus, may contribute to a
reduction in long-term microvascular and macrovascular
